Kun for helsepersonell

Søk 

Menu

Close

Logg innLogg ut
LegemiddelTerapiområdeUtforsk merUtforsk merMateriellVideo/podkastNyhetsbrevKontakt oss
Om

Menu

Close

EffektEffektdataStudiedesignKlinisk remisjonTidlig symptomatisk responsEndoskopisk forbedringBiologiske/JAKi-undergrupperIsolert proktittSikkerhetBivirkningerHjerte- og øyebivirkningerKom i gangOpplæringsmateriellMateriellVideo
Klinisk remisjon

ELEVATE UC 52

ELEVATE UC 12

Tab Number 3

Tab Number 4

Tab Number 5

VELSIPITY helped patients calm the UC symptoms1

Significant and sustained clinical remission* vs placebo in ELEVATE UC 521

Graph made by Pfizer based on reference 1, table 2
 

2 in 3 patients taking VELSIPITY who achieved clinical remission at week 12 sustained it at week 521

ReferencesClinical remission was defined as a stool frequency (SF) subscore of 0 (or of 1 with a ≥1-point decrease from baseline), a rectal bleeding (RB) subscore of 0, and an endoscopy score (ES) ≤1 (excluding friability).1Corticosteroid-free remission was defined as remission at week 52 without receiving corticosteroids for ≥12 weeks prior to week 52.1Investigators were directed to taper corticosteroids in ELEVATE UC 52 after the week 12 assessment.2Early symptomatic responseSee how VELSIPITY offered symptomatic response as early as week 2.LoadingTidlig symptomatisk responsReferences:VELSIPITY (etrasimod) Summary of Product Characteristics.Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies [published correction appears in Lancet. 2023;401(10381):1000]. Lancet. 2023;401(10383):1159-1171.
VELSIPITY helped patients calm the UC symptoms

Significant clinical remission* vs placebo in ELEVATE UC 121

References                                                                                                                   Graph made by Pfizer based on reference 1, table 2Clinical remission was defined as a stool frequency (SF) subscore of 0 (or of 1 with a ≥1-point decrease from baseline), a rectal bleeding (RB) subscore of 0, and an endoscopy score (ES) ≤1 (excluding friability).1Early symptomatic responseSee how VELSIPITY offered symptomatic response as early as week 22Tidlig symptomatisk responsLoadingReferences:VELSIPITY (etrasimod) Summary of Product Characteristics.Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies [published correction appears in Lancet. 2023;401(10381):1000]. Lancet. 2023;401(10383):1159-1171
Effekt

Preparatomtale

 
PP-V1A-NOR-0028 | Utarbeidet 11.2024

Pfizer AS, Org.nr 915 213 596

Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo

Tlf.: +47 67 52 61 00


PP-BCP-NOR-0001 juni 2023

Copyright © 2023 Pfizer AS. Innholdet er rettighetsbeskyttet.

 




 
Du forlater nå PfizerPro.no
Nettstedet du kommer til er hverken eid eller kontrollert av Pfizer i Norge. Pfizer i Norge er ikke ansvarlig for innholdet på nettstedet du kommer til.
Kun for helsepersonell

Dette nettstedet er kun for helsepersonell.

Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1.

Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.

Ja Nei